SEC 8-K filings with transcript text
Aug 15, 2017
8-K 1 form8-k.htm
Washington,
8-K
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 14, 2017
(Exact name of registrant as specified in its charter)
Delaware 000-19871 94-3078125
(State or other jurisdiction
of incorporation)
(Commission
File Number)
Employer
Identification No.)
25 Recreation Park Drive, Unit 108
Hingham, Massachusetts 02043
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 875-3605
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 2.02 Results of Operations and Financial Condition.
On August 14, 2017, Microbot Medical Inc. (the “Registrant”) issued a press release reporting on its results of operations for the second quarter ended June 30, 2017.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated August 14, 2017.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
By: /s/ Harel Gadot
Name: Harel Gadot
Title: Chairman, President and Chief Executive Officer
Date: August 14, 2017
May 15, 2017
8-K 1 form8-k.htm
Washington,
8-K
TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): May 15, 2017
(Exact Name of Registrant as Specified in Charter)
Delaware
000-19871
94-3078125
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
5 Hamada St.
Yokneam 2069204, Israel
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (908) 938-5561
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 2.02 Results of Operations and Financial Condition.
On May 15, 2017, Microbot Medical Inc. (the “Registrant”) issued a press release reporting on its results of operations for the first quarter ended March 31, 2017.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).
Item 9.01. Financial Statements and Exhibits.
Exhibit Number
Description
99.1
Press Release
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Harel Gadot
Name: Harel Gadot
Title: Chairman, President and Chief Executive Officer
Date: May 15, 2017
Mar 23, 2016
8-K 1 htm_53280.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 23, 2016
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On March 23, 2016, StemCells, Inc. (the "Company") issued a press release reporting its financial results for the three months and year ended December 31, 2015. A copy of this press release is attached hereto as Exhibit 99.1.The Company will host a live conference call and webcast on Thursday, March 24, 2016, at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time), to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of the Company's website at http://edge.media-server.com/m/p/asjrw2p9/lan/en. An archived version of the webcast will be available for replay on the Company's website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.Exhibit 99.1 Press Release, dated March 23, 2016, reporting the Company's financial results for the three months and year ended December 31, 2015.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
March 23, 2016
By:
Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press Release dated March 23, 2016
Nov 2, 2015
8-K 1 htm_52640.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 2, 2015
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On November 2, 2015, StemCells, Inc. (the "Company") issued a press release announcing its financial results for three months ended September 30, 2015. A copy of this press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
Exhibit 99.1 Press Release, dated November 2, 2015, announcing the Company’s financial results for the three months ended September 30, 2015.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
October 2, 2015
By:
Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated November 2, 2015
Aug 6, 2015
8-K 1 htm_52268.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 6, 2015
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2015, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2015. A copy of this press release is attached hereto as Exhibit 99.1.StemCells will host a live conference call and webcast today, August 6, at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss its financial results, recent business activities and clinical progress. Interested parties are invited to listen to the call over the Internet at: http://edge.media-server.com/m/p/78ib94kx. An archived version of the webcast will be available for replay beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days on the Company's website at http://investor.stemcellsinc.com/. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit 99.1 Press Release, dated August 6, 2015, announcing the Company's financial results for the three months ended June 30, 2015.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
August 6, 2015
By:
/s/ Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated August 6, 2015
May 5, 2015
8-K 1 htm_51759.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
May 5, 2015
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On May 5, 2015, StemCells, Inc. (the "Company") issued a press release announcing its financial results for three months ended March 31, 2015. A copy of this press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
Exhibit 99.1 Press Release, dated May 5, 2015, announcing the Company's financial results for the three months ended March 31, 2015.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
May 5, 2015
By:
Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
(d) Exhibits
Mar 16, 2015
8-K 1 htm_51454.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 16, 2015
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On March 16, 2015, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months and Year ended December 31, 2014. A copy of this press release is attached hereto as Exhibit 99.1.StemCells will host a live conference call and webcast on Monday, March 16, 2015 at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss our financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of our website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-calendar. An archived version of the webcast will be available for replay on our website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days.The information set forth in Items 2.02 and 9.01 of this current Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.Exhibit 99.1 Press Release, dated March 16, 2015, announcing the Company's financial results for the three months and year ended December 31, 2014.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
March 16, 2015
By:
Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated March 16, 2015
Nov 6, 2014
8-K 1 htm_50761.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 5, 2014
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2014, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2014. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host its first investor and analyst event November 20, from 12:00 to 2:30 pm EST, to provide updates on the ongoing Phase I/II clinical programs in dry age related macular degeneration (AMD) and spinal cord injury. Management will also provide updates and insights into the follow-on Phase II studies in both of these indications, including the recently initiated Pathway® Study in cervical spinal cord injury. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.Exhibit 99.1 Press Release, dated November 5, 2014, announcing the Company's financial results for the three months ended September 30, 2014.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
November 5, 2014
By:
/s/ Ken Stratton
Name: Ken Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated November 5, 2014
Aug 12, 2014
8-K 1 htm_50324.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 12, 2014
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On August 12, 2014, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2014. A copy of this press release is attached hereto as Exhibit 99.1. StemCells will host a live conference call and webcast today, August 12, at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of our website at http://edge.media-server.com/m/p/qhw8vz77/lan/en. An archived version of the webcast will be available for replay on the Company's website for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.Exhibit 99.1 Press Release, dated August 12, 2014, announcing the Company's financial results for the three months ended June 30, 2014.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
August 12, 2014
By:
/s/ Ken Stratton
Name: Ken Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated August 12, 2014
May 14, 2014
8-K 1 htm_49827.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
May 14, 2014
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On May 14, 2014, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2014. A copy of this press release is attached hereto as Exhibit 99.1. StemCells will host a live conference call and webcast today, May 14, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of our website at http://edge.media-server.com/m/p/w3fnraba/lan/en. An archived version of the webcast will be available for replay on the Company's website for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit 99.1 Press Release, dated May 14, 2014, announcing the Company's financial results for the three months ended March 31, 2014.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
May 14, 2014
By:
/s/ Ken Stratton
Name: Ken Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated May 14, 2014
Mar 12, 2014
8-K 1 htm_49447.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 12, 2014
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On March 12, 2014, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months and year ended December 31, 2013. A copy of this press release is attached hereto as Exhibit 99.1.StemCells will host a live conference call and webcast on Wednesday, March 12, 2014 at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss our financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of our website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-calendar. An archived version of the webcast will be available for replay on our website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.Exhibit 99.1 Press Release, dated March 12, 2014, announcing the Company's financial results for the three months and year ended December 31, 2013.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
March 12, 2014
By:
Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated March 12, 2014
Nov 5, 2013
8-K 1 htm_48772.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 5, 2013
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2013, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2013. A copy of this press release is attached hereto as Exhibit 99.1.StemCells will host a live conference call and webcast today, November 5, at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss our financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of our website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-calendar. An archived version of the webcast will be available for replay on our website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) ExhibitsExhibit 99.1 Press Release, dated November 5, 2013, announcing the Company's financial results for the three months ended September 30, 2013.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
November 5, 2013
By:
/s/ Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99
Press release dated November 5, 2013
Aug 7, 2013
8-K 1 htm_48266.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 7, 2013
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On August 7, 2013, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2013. A copy of this press release is attached hereto as Exhibit 99.1. StemCells will host a live conference call and webcast today, August 7, at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of our website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-calendar. An archived version of the webcast will be available for replay on the Company's website for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.Exhibit 99.1 Press Release, dated August 7, 2013, announcing the Company's financial results for the three months ended June 30, 2013.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
August 7, 2013
By:
/s/ Ken Stratton
Name: Ken Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated August 7, 2013
May 9, 2013
8-K 1 htm_47671.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
May 9, 2013
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2013, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2013. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a live conference call and webcast today, May 9, at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of our website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-calendar. An archived version of the webcast will be available for replay on our website for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.Exhibit 99.1 Press Release, dated May 9, 2013, announcing the Company's financial results for the three months ended March 31, 2013.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
May 9, 2013
By:
/s/ Ken Stratton
Name: Ken Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated May 9, 2013
Mar 21, 2013
8-K 1 htm_47344.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 19, 2013
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On March 19, 2013, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months and year ended December 31, 2012. A copy of this press release is attached hereto as Exhibit 99.1.StemCells will host a live conference call and webcast today, Thursday, March 21, at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss our financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of our website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-irhome. An archived version of the webcast will be available for replay on our website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) ExhibitsExhibit 99.1 Press Release, dated March 19, 2013, announcing the Company's financial results for the three months and year ended December 31, 2012.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
March 21, 2013
By:
/s/ Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated March 19, 2013
Nov 8, 2012
8-K 1 htm_46406.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 8, 2012
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On November 8, 2012, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2012. A copy of this press release is attached hereto as Exhibit 99.1.StemCells will host a live conference call and webcast today, November 8, at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss our financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of our website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-irhome. An archived version of the webcast will be available for replay on our website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) ExhibitsExhibit 99.1 Press Release, dated November 8, 2012, announcing the Company's financial results for the three months ended September 30, 2012.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
November 8, 2012
By:
/s/ Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated November 8, 2012
Aug 2, 2012
8-K 1 htm_45722.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 2, 2012
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On August 2, 2012, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2012. A copy of this press release is attached hereto as Exhibit 99.1.StemCells will host a live conference call and webcast today, August 2, at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of the Company’s website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-irhome. An archived version of the webcast will be available for replay on the Company’s website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) ExhibitsExhibit 99.1 Press Release, dated August 2, 2012, announcing the Company's financial results for the three months ended June 30, 2012.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
August 2, 2012
By:
/s/ Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press release dated August 2, 2012
May 10, 2012
8-K 1 htm_45025.htm
StemCells, Inc. (Form: 8-K)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
May 10, 2012
StemCells, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
7707 Gateway Blvd, Suite 140, Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
510.456.4000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 2.02 Results of Operations and Financial Condition.
On May 10, 2012, StemCells, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2012. A copy of this press release is attached hereto as Exhibit 99.1.StemCells will host a live conference call and webcast today, May 10, at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of the Company’s website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-irhome. An archived version of the webcast will be available for replay on the Company’s website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) ExhibitsExhibit 99.1 Press Release, dated May 10, 2012, announcing the Company's financial results for the three months ended March 31, 2012.
Top of the Form
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
May 10, 2012
By:
/s/ Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press Release of StemCells, Inc. dated May 10, 2012
Mar 13, 2012
8-K 1 d314798d8k.htm
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2012
StemCells, Inc. (Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
7707 Gateway Blvd, Suite 140, Newark,
California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: 510.456.4000
Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On March 13, 2012, StemCells, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2011. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a live conference call and webcast on March 13, 2012, at 4:30 PM Eastern Time (1:30 PM Pacific Time), to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of the Company’s website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-irhome. An archived version of the webcast will be available for replay on the Company’s website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 Press Release, dated March 13, 2012, announcing the Company’s financial results for the three months and year ended December 31, 2011.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
March 13, 2012
By:
/s/ Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Exhibit Index
Exhibit No.
Description
99.1
Press Release of StemCells, Inc. dated March 13, 2012
Nov 1, 2011
8-K 1 d249420d8k.htm
Form 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 1, 2011
StemCells, Inc. (Exact name of registrant as specified in its charter)
Delaware
000-19871
94-3078125
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
7707 Gateway Blvd, Suite 140,
Newark, California
94560
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: 510.456.4000
Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On November 1, 2011, StemCells, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2011. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a live conference call and webcast on November 1, 2011, at 4:30 PM Eastern Time (1:30 PM Pacific Time), to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of the Company’s website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-irhome. An archived version of the webcast will be available for replay on the Company’s website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. The information set forth in Items 2.02 and 9.01 of this current report Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 Press Release, dated November 1, 2011, announcing the Company’s financial results for the three months ended September 30, 2011.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc.
November 1, 2011
By:
/s/ Kenneth Stratton
Name: Kenneth Stratton
Title: General Counsel
Exhibit Index
Exhibit No.
Description
99.1
Press Release of StemCells, Inc. dated November 1, 2011
This page provides Microbot Medical Inc. (MBOT) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on MBOT's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.